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 CURRENTOPINION Living in interesting times – challenging protein
metabolism in the era of the epidemiological shift
Alessandro Laviano
The recently released results of the Global Burden of
Disease, Injuries, and Risk Factor study 2013 reveal
that during the past 23 years, metabolic and behav-
ioral risk factors, including high BMI, increased their
impact on global mortality and disability-adjusted
life-years [1]. These data highlight the importance of
the investigation of the metabolic impact of specific
nutrients and different eating behaviors on preserv-
ing and restoring the health of individuals and also
populations.
Protein metabolism is a key component of
human metabolism and is closely related to health
and resistance to exogenous and endogenous
insults. Acute and chronic diseases are characterized
by the progressive derangement of body compo-
sition, which is secondary, among other factors,
to increased proteolysis without the compensatory
increase of muscle anabolism [2]. The resulting
muscle loss is therefore the phenotype of the
molecular changes induced by the presence of a
disease. However, the molecular changes of protein
metabolism also result in clinically relevant con-
ditions. Muscle mass has been consistently demon-
strated to predict the rate of complications during
acute and chronic diseases. In particular, lowmuscle
mass, that is, sarcopenia, is associated to treatment-
related toxicity in cancer patients receiving chemo-
therapy or undergoing surgery [3,4]. Muscle wasting
has been for long considered unresponsive to nutri-
tional intervention because of inflammation-driven
anabolic resistance [5]. Emerging and convincing
data now suggest that muscle wasting can be effec-
tively prevented and treated by delivery of adequate
amount and specific types of amino acids (Engelen
et al., pp. 39–47), which, in turn, may enhance the
efficacy of anticancer treatments. Thus, anabolic
resistance of diseased states may actually be over-
come by timely and specific protein delivery.
On the contrary, disease-related early changes of
protein metabolism can be exploited as markers
of developing diseases. In this light, changes in
plasma branched-chain amino acid levels are closely
linked to the risk of developing diabetes (Giesbertz
and Daniel, pp. 48–54), whereas alterations of
tryptophan metabolism could be considered as
markers of neuroinflammation (Strasser et al.,
pp. 55–61). The progressive elucidation of the early
changes of protein metabolism and their relation-
ship with the risk of developing chronic diseases will
increase the efficacy of preventive and therapeutic
strategies. Nevertheless, these clinical achievements
will not be possible without a thorough assessment
of the interrelationships between different amino
acid metabolic pathways (Marini, pp. 62–66) and
the precise detailing of the mechanisms of amino
acid sensing (Ham et al., pp. 67–73).
Prevention of diseases is a key target for basic
and clinical research in the field of metabolism.
Whether specific dietary behaviors could yield to
healthy aging remains to be demonstrated in large,
prospective, randomized, clinical trials. However,
data emerging from animal studies could be verified
in large epidemiological databases, even if this
methodological approach cannot replace prospec-
tive studies. Significant scientific interest has been
devoted to protein intake as a dietary strategy to
slow aging and maintain functional independence.
However, recent analysis of epidemiological data-
bases suggests that high protein intake reduces
mortality in older adults, whereas it is associated
to increased mortality in younger adults (Mirzaei
et al., pp. 74–79). These results disclose the complex-
ity of humanmetabolism and underline the need for
carefully considering different factors before inter-
fering with it by using sometimes extreme dietary
strategies.
Life expectancy is gradually increasing, this
being associated with the progressive increase
of chronic and degenerative diseases, including
cancer [6]. Favoring the healthy aging of human
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population remains the imperative goal to not only
preserve the economic sustainability of healthcare
systems but also maintain social stability. The better
understanding of human metabolism and, in
particular, its interactions with the external, that
is, nutrients, pollutants, and others, and the internal
environment, that is, microbiota, oxidative stress,
and others, will pave the way to new and effective
preventive and therapeutic strategies. In this light,
exciting data are emerging from the study of protein
metabolism at different ages and after different
challenges. And more is to come.
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